RAMES study: is there really a role for VEGF inhibition in mesothelioma? - Authors' reply

Lancet Oncol. 2021 Dec;22(12):e533. doi: 10.1016/S1470-2045(21)00666-5.

Authors

Paolo Andrea Zucali¹, Carmine Pinto², Giovanni Luca Ceresoli³; RAMES investigators

Affiliations

¹ Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; Department of Oncology, IRCCS Humanitas Research Hospital, 20089 Rozzano, Milan, Italy. Electronic address: paolo.zucali@hunimed.eu.
² Medical Oncology Unit, Clinical Cancer Centre, AUSL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
³ Thoracic and GU Oncology Unit, Department of Medical Oncology, Cliniche Humanitas Gavazzeni, Bergamo, Italy.

PMID: 34856143
DOI: 10.1016/S1470-2045(21)00666-5

No abstract available

Publication types

Letter
Comment

MeSH terms

Humans
Mesothelioma* / drug therapy
Mesothelioma, Malignant*
Pleural Neoplasms*
Vascular Endothelial Growth Factor A

Substances

Vascular Endothelial Growth Factor A